Evidence map›Paper›PMID 41991649›Full record

ArticleScientific reports2026

Dual antiviral and anti-inflammatory effects of BAY 11-7082 in SARS-CoV-2 infection via inhibition of the canonical NF-κB signaling pathway.

Po-Chih Wu, Meng-Chang Lee, Ming-Sian Wu, Chun-Hsi Tso, Jia-Chuan Hsu, Der-Yuan Wang, Hao-Ai Shui, Chi-Tun Tang, Chia-Wen Shih, Chin-Mao Hung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Po-Chih WuGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei City, 114201, Taiwan.
Meng-Chang LeeGraduate Institute of Public Health, College of Public Health, National Defense Medical University, Taipei City, 114201, Taiwan.
Ming-Sian WuDivision of Research and Analysis, Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taipei City, 115209, Taiwan.
Chun-Hsi TsoDivision of Research and Analysis, Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taipei City, 115209, Taiwan.
Jia-Chuan HsuDivision of Research and Analysis, Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taipei City, 115209, Taiwan.
Der-Yuan WangDivision of Research and Analysis, Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taipei City, 115209, Taiwan.
Hao-Ai ShuiGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei City, 114201, Taiwan.
Chi-Tun TangDepartment of Neurological Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei City, 114202, Taiwan.
Chia-Wen ShihGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei City, 114201, Taiwan.
Chin-Mao HungGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei City, 114201, Taiwan. chinmaohung@mail.ndmctsgh.edu.tw.

Funding

National Defense Medical University MND-MAB-E-113081Tri-Service General Hospital TSGH-E-111227
6 · The paper itself

Abstract

The continued emergence of SARS-CoV-2 variants and persistent inflammatory complications of COVID-19 highlight the urgent need for therapeutics with both antiviral and anti-inflammatory properties. Despite intensive global efforts, no approved antiviral therapy with these dual functions has yet been developed, representing a significant gap in current COVID-19 treatment strategies. In this study, we identify BAY 11-7082 (BAY) as a dual-action compound that inhibits SARS-CoV-2 replication and the production of virus-induced pro-inflammatory cytokines and chemokines, including IL-6, IL-8, CXCL1, and CXCL2. BAY predominantly exerts its antiviral activity at the post-entry stage of the viral life cycle. Mechanistically, BAY potentially interacts with SARS-CoV-2 NSP14 and inhibits virus-induced phosphorylation and degradation of IκBα, suppressing NF-κB activation through the IKK-IκBα signaling axis. Furthermore, BAY exhibits potent antiviral activity against multiple SARS-CoV-2 variants of concern (VOCs). Collectively, these findings support the potential of BAY as a dual-action therapeutic candidate, combining antiviral and anti-inflammatory effects, against SARS-CoV-2 and its emerging variants.

Indexed as

Anti-Inflammatory AgentsAntiviral AgentsCOVID-19 Drug TreatmentNF-kappa BNitrilesSARS-CoV-2Signal TransductionSulfonesAnimalsChlorocebus aethiopsCOVID-19CytokinesHumansI-kappa B KinaseNF-KappaB Inhibitor alphaVero Cells3-(4-methylphenylsulfonyl)-2-propenenitrileAnti-Inflammatory AgentsAntiviral AgentsCytokinesI-kappa B KinaseNF-kappa BNF-KappaB Inhibitor alphaNitrilesSulfonesAnti-inflammatoryAntiviral therapyBAY 11-7082Canonical NF-κB signaling pathwayNSP14SARS-CoV-2

Identifiers

PMID41991649
PMCPMC13247045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.